Boston Biomedical begins Phase III CanStem303C study of napabucasin to treat colorectal cancer

Boston Biomedical has dosed the first patient in CanStem303C, a new global Phase III study investigating napabucasin in combination with standard of care (FOLFIRI) in patients with previously treated metastatic colorectal carcinoma (mCRC).

Source: Drug Development Technology - October 24, 2016 Category: Pharmaceuticals Source Type: news